Celgene and IBM Watson Health have inked a collaboration to co-develop IBM Watson for Patient Safety, a new offering that aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions. The new offering will run on the Watson Health Cloud.

The collaboration will combine Watson’s cognitive computing ability with Celgene’s experience in drug safety and risk management, in order to create an outcome- and evidence-based drug safety decision support system for life science companies, said IBM in a statement.

Watson for Patient Safety will be developed in phases, with the first module anticipated within the next year. Watson Health Cloud for Life Sciences Compliance offers a health-data enabled infrastructure and is designed to streamline GxP compliance, says IBM.

[Image courtesy: IBM]